NCT04847050 · OUTCOME

Number of Participants Who Had Vital Signs Performed Prior to Vaccine

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy · Source last updated 2024-08-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: Prior to each vaccine. Screening or Day 0 visit; Day 1, visit 1, vaccine dose 1; Day 29, visit 2, vaccine dose 2; Day 209 (6 months), visit 5 (+/- 28 days); and Day 394, visit 6 (+/- 28 days)

What was measured

Vital signs: weight, temperature, heart rate/pulse, respirations, and blood pressure will be performed prior to each vaccine.

Groups in this outcome

Hematologic Low Immunosuppression - Initial Phase

100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on days 1 and 29; with option for subsequent booster dose, 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29.

Hematologic Intermediate Immunosuppression - Initial Phase

Hematologic High Immunosuppression - Initial Phase

Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase

Other Hematologic Malignancy - Booster Phase

100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on day 1.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Hematologic Low Immunosuppression - Initial Phase	2
Hematologic Intermediate Immunosuppression - Initial Phase	3
Hematologic High Immunosuppression - Initial Phase	7
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3
Other Hematologic Malignancy - Booster Phase	4

Reported measurements

Screening or Day 0 visit - Weight

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	7	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	4	Not reported	Not reported	Not reported	Not reported

Screening or Day 0 visit -Temperature

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	7	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	4	Not reported	Not reported	Not reported	Not reported

Screening or Day 0 visit - Heart rate/Pulse

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	7	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	4	Not reported	Not reported	Not reported	Not reported

Screening or Day 0 visit - Respirations

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	7	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	4	Not reported	Not reported	Not reported	Not reported

Screening or Day 0 visit - Blood Pressure

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	7	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	4	Not reported	Not reported	Not reported	Not reported

Day 1, visit 1, vaccine dose 1 - Weight

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	7	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 1, visit 1, vaccine dose 1 - Temperature

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	7	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 1, visit 1, vaccine dose 1 - Heart rate/Pulse

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	7	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 1, visit 1, vaccine dose 1 - Respirations

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	7	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 1, visit 1, vaccine dose 1 - Blood Pressure

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	7	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 29, visit 2, vaccine dose 2 - Weight

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	Not reported	Not reported	Not reported	Not reported

Day 29, visit 2, vaccine dose 2 - Temperature

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	6	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 29, visit 2, vaccine dose 2 - Heart rate/Pulse

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	6	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 29, visit 2, vaccine dose 2 - Respirations

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	6	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 29, visit 2, vaccine dose 2 - Blood Pressure

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	6	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 209 (6 months), visit 5 (+/- 28 days) - Weight

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	Not reported	Not reported	Not reported	Not reported

Day 209 (6 months), visit 5 (+/- 28 days) - Temperature

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	1	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	1	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 209 (6 months), visit 5 (+/- 28 days) - Heart rate/Pulse

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	1	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	1	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 209 (6 months), visit 5 (+/- 28 days) - Respirations

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	1	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	1	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 209 (6 months), visit 5 (+/- 28 days) - Blood Pressure

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	1	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	2	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	1	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 394, visit 6 (+/- 28 days) - Weight

Values in Participants · Interval/dispersion: Not reported
Group	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	Not reported	Not reported	Not reported	Not reported

Day 394, visit 6 (+/- 28 days) - Temperature

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 394, visit 6 (+/- 28 days) - Heart rate/Pulse

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 394, visit 6 (+/- 28 days) - Respirations

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Day 394, visit 6 (+/- 28 days) - Blood Pressure

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Hematologic Low Immunosuppression - Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Hematologic Intermediate Immunosuppression - Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Hematologic High Immunosuppression - Initial Phase	3	Not reported	Not reported	Not reported	Not reported
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase	0	Not reported	Not reported	Not reported	Not reported
Other Hematologic Malignancy - Booster Phase	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
7
group Id
OG003
value
3
group Id
OG004
value
4
title
Screening or Day 0 visit - Weight
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
7
group Id
OG003
value
3
group Id
OG004
value
4
title
Screening or Day 0 visit -Temperature
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
7
group Id
OG003
value
3
group Id
OG004
value
4
title
Screening or Day 0 visit - Heart rate/Pulse
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
7
group Id
OG003
value
3
group Id
OG004
value
4
title
Screening or Day 0 visit - Respirations
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
7
group Id
OG003
value
3
group Id
OG004
value
4
title
Screening or Day 0 visit - Blood Pressure
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
7
group Id
OG003
value
3
group Id
OG004
value
0
title
Day 1, visit 1, vaccine dose 1 - Weight
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
7
group Id
OG003
value
3
group Id
OG004
value
0
title
Day 1, visit 1, vaccine dose 1 - Temperature
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
7
group Id
OG003
value
3
group Id
OG004
value
0
title
Day 1, visit 1, vaccine dose 1 - Heart rate/Pulse
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
7
group Id
OG003
value
3
group Id
OG004
value
0
title
Day 1, visit 1, vaccine dose 1 - Respirations
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
7
group Id
OG003
value
3
group Id
OG004
value
0
title
Day 1, visit 1, vaccine dose 1 - Blood Pressure
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
group Id
OG002
value
0
group Id
OG003
value
0
group Id
OG004
value
0
title
Day 29, visit 2, vaccine dose 2 - Weight
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
6
group Id
OG003
value
3
group Id
OG004
value
0
title
Day 29, visit 2, vaccine dose 2 - Temperature

denoms

counts
group Id
OG000
value
2
group Id
OG001
value
3
group Id
OG002
value
7
group Id
OG003
value
3
group Id
OG004
value
4
units
Participants

description

Vital signs: weight, temperature, heart rate/pulse, respirations, and blood pressure will be performed prior to each vaccine.

groups

description
100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on days 1 and 29; with option for subsequent booster dose, 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29.
id
OG000
title
Hematologic Low Immunosuppression - Initial Phase
description
100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on days 1 and 29; with option for subsequent booster dose, 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29.
id
OG001
title
Hematologic Intermediate Immunosuppression - Initial Phase
description
100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on days 1 and 29; with option for subsequent booster dose, 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29
id
OG002
title
Hematologic High Immunosuppression - Initial Phase
description
100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on days 1 and 29; with option for subsequent booster dose, 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29.
id
OG003
title
Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Initial Phase
description
100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on day 1.
id
OG004
title
Other Hematologic Malignancy - Booster Phase

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

Prior to each vaccine. Screening or Day 0 visit; Day 1, visit 1, vaccine dose 1; Day 29, visit 2, vaccine dose 2; Day 209 (6 months), visit 5 (+/- 28 days); and Day 394, visit 6 (+/- 28 days)

title

Number of Participants Who Had Vital Signs Performed Prior to Vaccine

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice